ChromaCode
Justin Klein, MD, JD, is a co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. Justin was previously a partner and leader of the medical technology investing practice at NEA and worked at the Duke University Health System in strategy, operations, and finance. Justin currently or previously served on the board of directors of Apella, Cartiva (acquired), ChromaCode, Cleerly, Curate Biosciences, CV Ingenuity (acquired), Epix Therapeutics (acquired), FIRE1, Intact Vascular (acquired), Metavention, Personal Genome Diagnostics (acquired), PhaseBio Pharmaceuticals (IPO), Plexium, Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical (acquired), and VytronUS (acquired).
This person is not in the org chart
This person is not in any offices
ChromaCode
ChromaCode is a molecular diagnostics company with a bioinformatics focus and pedigree from Illumina, Google[x], Luminex, and Caltech. They leverage patented mathematical methods and algorithmic enhancements to enrich signal processing from the most popular life science instrumentation. They use this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost.